Home Report Catalogue Pharmaceuticals APAC Multiple Sclerosis Drugs Market Analysis
Pharmaceuticals APAC

APAC Multiple Sclerosis Drugs Market Analysis, 2024–2034

APAC Multiple Sclerosis Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.84 Bn Estimated value
Estimate 2025 $5.04 Bn 18.4% of the global market
Projected 2034 $7.23 Bn 43.6% Adds $2.20 Bn over 9 forecast years
CAGR 2025–2034 4.1% Faster than 3% of 180 Pharmaceuticals markets here
Key players 6 +1
  • APAC is 18.44% of the global market.
  • Among regions, the largest is North America at $13.58 Bn.
  • Fastest growing: APAC (this report) at 4.1% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.20 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Multiple Sclerosis Drugs Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.84 Bn — —
2025 (base) $5.04 Bn +$198.4 Mn —
2026 (forecast) $5.24 Bn +$206.6 Mn +4.1%
2027 (forecast) $5.46 Bn +$215.0 Mn +8.4%
2028 (forecast) $5.68 Bn +$223.9 Mn +12.8%
2029 (forecast) $5.92 Bn +$233.0 Mn +17.4%
2030 (forecast) $6.16 Bn +$242.6 Mn +22.3%
2031 (forecast) $6.41 Bn +$252.5 Mn +27.3%
2032 (forecast) $6.67 Bn +$262.9 Mn +32.5%
2033 (forecast) $6.95 Bn +$273.7 Mn +37.9%
2034 (forecast) $7.23 Bn +$284.9 Mn +43.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $27.32 Bn
  2. North America $13.58 Bn
  3. US $12.33 Bn
  4. Europe $5.60 Bn
  5. APAC (this report) $5.04 Bn
  6. China $2.57 Bn
  7. Canada $2.43 Bn
  8. Japan $1.55 Bn
  9. Latin America $1.35 Bn
  10. Middle East $1.22 Bn
  11. Germany $1.05 Bn
  12. UK $755.0 Mn
  13. France $739.5 Mn
  14. Italy $703.0 Mn
  15. Brazil $627.4 Mn
  16. Ecuador $555.8 Mn
  17. India $583.3 Mn
  18. Spain $468.3 Mn
  19. Mexico $475.3 Mn
  20. Saudi Arabia $447.7 Mn
  21. Africa $390.8 Mn
  22. Russia $303.3 Mn
  23. Australia $313.0 Mn
  24. New Zealand $259.2 Mn
  25. South Africa $163.4 Mn
  26. UAE $142.7 Mn
  27. Egypt $77.1 Mn
  28. Philippines $67.2 Mn
  29. Malaysia $42.1 Mn
  30. Hong Kong $39.6 Mn
  31. Thailand $37.9 Mn
  32. Singapore $31.4 Mn
  33. Kenya $19.6 Mn

The APAC Multiple Sclerosis Drugs Market Analysis Executive Summary

Multiple sclerosis drugs reduce relapses and slow disability in this immune disease of the brain and spinal cord.

Key segments of the multiple Sclerosis Drugs market include drug class (Anti-CD20 Antibodies, S1P Modulators and Interferons) and route (Infusion, Injectable and Oral).

APAC Multiple Sclerosis Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the multiple Sclerosis Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the multiple Sclerosis Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the multiple Sclerosis Drugs market.

Competitive Landscape for Multiple Sclerosis Drugs Market in APAC

The multiple Sclerosis Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Multiple Sclerosis Drugs Market in APAC

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for multiple Sclerosis Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Multiple Sclerosis Drugs in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Alzheimer's Diagnosis: Blood Tests and Earlier Answers57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help… Cannabis-Based Medicines: Science and RegulationThe FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in APAC

See all
Same topic, other categories

Related on autoimmune diseases and brain and nerves

See the topic